Corpus overview


MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

ProteinS (1)


SARS-CoV-2 Proteins
    displaying 1 - 2 records in total 2
    records per page

    Tissue-resident memory CD8 HGNC T-cell responses elicited by a single injection of a multi-target COVID-19 MESHD vaccine

    Authors: Vanessa Gauttier; Aurore Morello; Isabelle Girault; Caroline Mary; Lyssia Belarif; Arianne Desselle; Emmanuelle Wilhelm; Thomas Bourquard; Sabrina Pengam; Geraldine Teppaz; Virginie Thepenier; Kevin Biteau; Estelle De Barbeyrac; Delphine Kiepferle; Berangere Vasseur; Francois-Xavier Le Flem; Didier Debieuvre; Dominique Costantini; Nicolas Poirier

    doi:10.1101/2020.08.14.240093 Date: 2020-08-14 Source: bioRxiv

    The COVID-19 MESHD COVID-19 MESHD pandemic is caused by severe acute respiratory syndrome coronavirus-2 MESHD (SARS-CoV-2) which enters the body principally through the nasal and larynx mucosa and progress to the lungs through the respiratory tract. SARS-CoV-2 replicates efficiently in respiratory epithelial cells motivating the development of alternative and rapidly scalable vaccine inducing mucosal protective and long-lasting immunity. We have previously developed an immunologically optimized multi-neoepitopes-based peptide vaccine platform which has already demonstrated tolerance and efficacy in hundreds of lung cancer MESHD patients. Here, we present a multi-target CD8 HGNC T cell peptide COVID-19 MESHD vaccine design targeting several structural (S, M, N) and non-structural (NSPs) SARS-CoV-2 proteins MESHD with selected epitopes in conserved regions of the SARS-CoV-2 genome. We observed that a single subcutaneous injection of a serie of epitopes induces a robust immunogenicity in-vivo as measured by IFN{gamma HGNC} ELIspot. Upon tetramer characterization we found that this serie of epitopes induces a strong proportion of virus-specific CD8 HGNC T cells expressing CD103 HGNC, CD44 HGNC, CXCR3 HGNC and CD49a HGNC, the specific phenotype of tissue-resident memory T lymphocytes (Trm). Finally, we observed broad cellular responses, as characterized by IFN{gamma HGNC} production, upon restimulation with structural and non-structural protein-derived epitopes using blood T cells isolated from convalescent asymptomatic, moderate and severe COVID-19 MESHD patients. These data provide insights for further development of a second generation of COVID-19 MESHD vaccine focused on inducing lasting Th1-biased memory CD8 HGNC T cell sentinels protection using immunodominant epitopes naturally observed after SARS-CoV-2 infection MESHD resolution. Statement of SignificanceHumoral and cellular adaptive immunity are different and complementary immune defenses engaged by the body to clear viral infection. While neutralizing antibodies have the capacity to block virus binding to its entry receptor expressed on human cells, memory T lymphocytes have the capacity to eliminate infected cells and are required for viral clearance. However, viruses evolve quickly, and their antigens are prone to mutations to avoid recognition by the antibodies (phenomenon named antigenic drift). This limitation of the antibody-mediated immunity could be addressed by the T-cell mediated immunity, which is able to recognize conserved viral peptides from any viral proteins presented by virus-infected cells. Thus, by targeting several proteins and conserved regions on the genome of a virus, T-cell epitope-based vaccines are less subjected to mutations and may work effectively on different strains of the virus. We designed a multi-target T cell-based vaccine containing epitope regions optimized for CD8 HGNC+ T cell stimulation that would drive long-lasting cellular immunity with high specificity, avoiding undesired effects such as antibody-dependent enhancement (ADE) and antibody-induced macrophages hyperinflammation that could be observed in subjects with severe COVID-19 MESHD. Our in-vivo results showed that a single injection of selected CD8 HGNC T cell epitopes induces memory viral-specific T-cell responses with a phenotype of tissue-resident memory T cells (Trm). Trm has attracted a growing interest for developing vaccination strategies since they act as immune sentinels in barrier tissue such as the respiratory tract and the lung. Because of their localization in tissues, they are able to immediately recognize infected cells and, because of their memory phenotypes, they rapidly respond to viral infection by orchestrating local protective immune responses to eliminate pathogens. Lastly, such multiepitope-based vaccination platform uses robust and well-validated synthetic peptide production technologies that can be rapidly manufactured in a distributed manner.

    Cross-reactivity of neutralizing antibody and its correlation with circulating T follicular cells in recovered COVID-19 MESHD individuals

    Authors: Jian Zhang; Xiaowang Qu

    doi:10.1101/2020.06.12.20129460 Date: 2020-06-14 Source: medRxiv

    Seroconversion appeared early after COVID-19 MESHD onset, and convalescent sera therapy benefit some critical patients. However, neutralizing antibody (nAb) in convalescents is largely unknown. We found that 97.01% (65/67) of COVID-19 MESHD convalescents maintained IgG antibodies with high binding and avidity to SARS-CoV-2 spike PROTEIN subunits S1 and S2, and 95.52% (64/67) had neutralization activity against SARS-CoV-2 pesudovirus, one month after discharge (median ID50, 2.75; IQR, 2.34-3.08). Some sera exhibited cross-neutralization against SARS-CoV (76.12%), MERS-CoV MESHD (17.91%), or both (10.45%). Interestingly, individuals recovered from severe disease (severe group) had nAbs with binding and neutralization titers higher than non-severe group. Severe group appeared a rapid increase of lymphocytes and a high proportion of circulating CXCR3 HGNC+ Tfh cells. Interestingly, the later were spike-specific and positively correlated with SARS-CoV-2 nAb titers MESHD. All subjects had no autoimmunity. Our findings provide novel insights into nAb responses in COVID-19 MESHD convalescents and facilitate treatment and vaccine development for SARS-CoV-2 infection MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.